About 22 results found for searched term "JAK2-IN-9" (0.164 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41714 | JAK2-IN-9 | JAK |
| JAK2-IN-9 is a selective JAK2 inhibitor (IC50: 5 nM). | ||
| M2039 | Baricitinib | JAK |
| INCB28050, LY3009104 | ||
| Baricitinib (INCB28050) is an oral JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively. | ||
| M4870 | Cerdulatinib | JAK |
| PRT062070, PRT2070 | ||
| Cerdulatinib (PRT-062070, PRT2070) is an orally active multi-target tyrosine kinase inhibitor with IC50s of JAK1/JAK2/JAK3/TYK2 and Syk 12 nM/6 nM/8 nM/0.5 nM and 32 nM, respectively. It was also able to inhibit the other 19 kinases tested, all with IC50 below 200 nM. | ||
| M5315 | Baricitinib phosphate | JAK |
| INCB028050; LY3009104 | ||
| Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. | ||
| M6297 | Upadacitinib | JAK |
| ABT-494 | ||
| Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research. | ||
| M8090 | PF-04965842 | JAK |
| Abrocitinib | ||
| Abrocitinib is an orally active and selective JAK1 inhibitor with an IC50 value of 29 nM. Abrocitinib reversibly inhibits JAK1 kinase by blocking its ATP-binding site. Abrocitinib (PF-04965842) inhibited TYK2 activity (IC50, 1.253 μM) and phosphorylation of STAT1, STAT3, and STAT5 after stimulation. It can be used in the study of autoimmune diseases. | ||
| M10437 | PF-06700841 | JAK |
| PF-06700841 free base; Brepocitinib | ||
| PF-06700841 is a first-in-class oral dual inhibitor of JAK1 and TYK2 with IC50 values of 17 nM and 23 nM, respectively.PF-06700841 also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively. | ||
| M27897 | SD-1029 | JAK |
| SD-1029 is a JAK2/STAT3 inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation. | ||
| M28015 | Ilginatinib hydrochloride | JAK |
| NS-018 hydrochloride | ||
| Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). | ||
| M28016 | Ilginatinib | JAK |
| NS-018 | ||
| Ilginatinib (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). | ||
| M28231 | Ilginatinib maleate | JAK |
| NS-018 maleate | ||
| Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). | ||
| M30803 | SC99 | STAT |
| SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities. | ||
| M41702 | JAK-IN-27 | JAK |
| JAK-IN-27 is an orally active and potent JAKS family kinase inhibitor with IC50s of 3.0 nM (TYK2), 7.7 nM (JAK1), 629.6 nM (JAK3), respectively. | ||
| M49571 | JAK1/TYK2-IN-1 | JAK |
| JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 (IC50 = 29 and 41 nM respectively). | ||
| M49573 | JAK1/TYK2-IN-4 | JAK |
| JAK1/TYK2-IN-4 is a dual inhibitor of JAK and TYK2, with IC50s of 39 nM and 21 nM, respectively. | ||
| M49580 | JAK-2/3-IN-2 | JAK |
| JAK-2/3-IN-2 is a JAK2 and JAK3 inhibitor with IC50s of 23.85 nM and 18.9 nM, respectively. | ||
| M49581 | JAK2/FLT3-IN-1 | JAK |
| JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. | ||
| M49582 | JAK2/TYK2-IN-1 | JAK |
| JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC50 values of 9 and 157 nM for TYK2 and JAK2, respectively. | ||
| M49593 | JAK3-IN-12 | JAK |
| JAK3-IN-12 is a highly potent JAK3 inhibitor with IC50 values of 9.5 nM, 18 nM and 42 nM for JAK3, JAK1 and JAK2, respectively. | ||
| M49603 | JAK-IN-21 | JAK |
| JAK-IN-21 is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively. | ||
| M49651 | JAK2/FLT3-IN-1 TFA | JAK |
| JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. | ||
| M53314 | Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) | JAK |
| Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
